Headlines Covid-19 Specialties Trending Feeds Videos

The COVID-19 pandemic has caused a worldwide healthcare crisis. In addition to the morbidity caused by the initial infection, severely ill patients are also...

Extended follow-up of patients enrolled in the ongoing phase 2 DREAMM-2 study confirms sustained clinical activity without new safety signals in patients with relapsed...

Blood Cancer Journal – Treatment patterns and outcomes in elderly patients with newly diagnosed...

Recently, The ASCO Post published an article titled “Defining Cure in Multiple Myeloma: A Conversation With S. Vincent Rajkumar, MD.” On this episode of...

The FDA has issued an alert that evidence from the phase 3 OCEAN study of melphalan flufenamide, which was recently approved for use in...

This Viewpoint discusses studies on the use of lenalidomide and dexmethasone and carfilzomib, lenalidomide, and dexamethasone treatment regimens for multiple...

On May 25, 2021, positive topline results from the phase III OCEAN study (NCT03151811) of melphalan flufenamide (melflufen) for the treatment of relapsed/refractory multiple...

This volume provides an overview of targeted therapies in Multiple Myeloma, disease biology, strategies to overcome resistance, and future...